Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacogenomic study of tolvaptan efficacy and adverse reactions in heart failure
ChiCTR1900023092Phase 4Not yet recruiting
- Sponsor
- Aelan Cell Technologies
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tolvaptan in heart failure (HF), sponsored by Aelan Cell Technologies. Primary endpoints: weight, blood concentration and 1 more. Planned start May 2019; status: not yet recruiting.
02
Drugs
tolvaptan
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on ChiCTR1900023092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900023092.